{
    "organizations": [],
    "uuid": "d1603cfb4a32e6e2e4e8e8c62771c8a635f99362",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ablynx-announces-topline-results-f/brief-ablynx-announces-topline-results-from-phase-ii-study-of-vobarilizumab-idUSFWN1R8012",
    "ord_in_thread": 0,
    "title": "BRIEF-Ablynx ‍Announces Topline Results From Phase II Study Of Vobarilizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - ABLYNX NV:\n* ‍ANNOUNCES TOPLINE RESULTS FROM PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS​\n* PHASE II DOSE-RANGING STUDY OF VOBARILIZUMAB DID NOT MEET PRIMARY ENDPOINT OF DOSE RESPONSE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-26T13:15:00.000+03:00",
    "crawled": "2018-03-27T12:12:37.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ablynx",
        "nv",
        "topline",
        "result",
        "phase",
        "ii",
        "study",
        "vobarilizumab",
        "patient",
        "systemic",
        "lupus",
        "phase",
        "ii",
        "study",
        "vobarilizumab",
        "meet",
        "primary",
        "endpoint",
        "dose",
        "response",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}